This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
The content of this website has been produced in line with the INLYTA® (axitinib) Summary of Product Characteristics for Great Britain.
Prescribing Information for INLYTA® (axitinib) click here. Prescribing Information for SUTENT® (sunitinib malate) click here. Adverse event reporting information can be found at the bottom of the page.
INLYTA® is an inhibitor of multiple receptor tyrosine kinases (TKIs), including vascular endothelial growth factor receptors (VEGFR) required for angiogenesis.1 Dysregulation of the VEGF pathway is frequently associated with RCC, due to loss of function of the von Hippel-Lindau gene2, making mRCC a highly vascular tumour, and underlying why the VEGF pathway continues to be a target in RCC.2
'Half-life' is an estimate of the time that it takes for the amount of medicine in the body (usually measured as blood concentration) to be reduced by half
The short half-life of INLYTA® ensures that it is cleared more quickly following dose interruptions/discontinuations3,4
| INLYTA® | 2.5-6.1 hours |
| Sorafenib | ~ 25-48 hours |
| Lenvantinib | ~ 28 hours |
| Everolimus | ~ 30 hours |
| Cabozantinib | ~ 110 hours |
| Tivozanib | 108-122.4 hours |
| Sunitinib | 40-60 hours (Sunitinib) and 80-110 hours (active metabolite of Sunitinib) |
| Pazopanib | 30.9 hours |
| Nivolumab | 25 days |
A short half-life means that AEs have the potential to be resolved quickly after treatment interruption4
A randomised, multicentre, Phase III trial in 723 patients with mRCC with disease progression on first-line therapy (sunitinib or cytokine), comparing the efficacy and safety of INLYTA® 5mg twice daily and sorafenib 400 mg twice daily.
In a phase III clinical trial, INLYTA® demonstrated superior efficacy over sorafenib as second-line therapy2,3
Kaplan-Meler curve of progression-free survival assessed by blinded independent radiology review committee for the overal ITT population (adapted from INLYTA® Summary of Product Characteristics)2,3
ORR in the overall ITT population assessed by blinded independent radiology review committee (adapted from INLYTA® Summary of Product Characteristics)2,3
RCC : Renal Cell Carcinoma, aRCC : advanced Renal Cell Carcinoma
References
INLYTA® is indicated for the treatment of adult patients with advanced renal cell carcinoma (aRCC) after failure of prior treatment with sunitinib or a cytokine1
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2023 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021